Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Acta Psychiatrica Scandinavica

• Publication date

  2007-04-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1111/j.1600-0447.2006.00897.xPMID 17355517
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antipsychotic-induced hyperprolactinemia and sexual dysfunction.

  2025cited by this paper
• Five‐year follow‐up during antipsychotic treatment: efficacy, safety, functional and social outcome

  2007cited by this paper
• Weight development in patients treated with risperidone: a 5‐year naturalistic study

  2007cited by this paper
• Effect of spinal cord transection upon the skeletal changes induced by aminoacetonitrile (AAN)

  2005cited by this paper
• Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia

  2005cited by this paper
• Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics

  2005cited by this paper
• Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.

  2005cited by this paper
• Osteoporosis in patients with schizophrenia.

  2005cited by this paper
• A preliminary study of sex-related differences in prolactin responses to dopamine blockade and insulin hypoglycemia and in penfluridol plasma levels in schizophrenic patients

  2004cited by this paper
• Gender differences in age at onset of Schizophrenia

  2004cited by this paper
• Stability of serum neuroleptic and prolactin concentrations during short- and long-term treatment of schizophrenic patients

  2004cited by this paper
• Sexual dysfunction with psychotropic drugs

  2003cited by this paper
• Sexual dysfunction and antipsychotic treatment.

  2003cited by this paper
• Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials.

  2003cited by this paper
• A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia.

  2003cited by this paper
• Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia.

  2002cited by this paper
• Elevation of prolactin levels by atypical antipsychotics.

  2002cited by this paper
• The Effects of Atypical Antipsychotics on Serum Prolactin Levels

  2002cited by this paper
• Antipsychotic Drugs and Obesity: Is Prolactin Involved?

  2001cited by this paper
• Beta cell proliferation and growth factors

  1999cited by this paper
• Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia.

  1995cited by this paper
• Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol

  1995cited by this paper
• Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia.

  1994cited by this paper
• Changes in Single Symptoms and Separate Factors of the Schizophrenic Syndrome after Treatment with Risperidone or Haloperidol

  1994cited by this paper
• A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.

  1993cited by this paper
• Effect of homologous placental lactogens, prolactins, and growth hormones on islet B-cell division and insulin secretion in rat, mouse, and human islets: implication for placental lactogen regulation of islet function during pregnancy.

  1993cited by this paper
• Effects of steroid and lactogenic hormones on islets of Langerhans: a new hypothesis for the role of pregnancy steroids in the adaptation of islets to pregnancy.

  1993cited by this paper
• The role of growth hormone and prolactin in beta cell growth and regeneration.

  1992cited by this paper
• Risperidone: clinical safety and efficacy in schizophrenia.

  1992cited by this paper
• Prolactin and Growth Hormone in the Regulation of the Immune System

  1991cited by this paper
• Gender differences in the course of schizophrenia.

  1988cited by this paper
• Gender differences in age at onset of schizophrenia. An overview.

  1988cited by this paper
• The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients

  1987cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper
• Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.

  1987cited by this paper
• Possible associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated male schizophrenics.

  1986cited by this paper
• Schizophrenia with Good and Poor Outcome. I: Early Clinical Features, Response to Neuroleptics and Signs of Organic Dysfunction

  1985cited by this paper
• Interaction of sex, age, and neuroleptic dose.

  1983cited by this paper
• Adverse effects of anticholinergic medication on positive schizophrenic symptoms

  1983cited by this paper
• Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients

  1983cited by this paper
• Short- and long-term fluctuations in plasma prolactin concentration in normal subjects.

  1981cited by this paper
• Tolerance to the prolactin-elevating effect of neuroleptics.

  1981cited by this paper
• The relationship of demographic, clinical, and outcome variables to neuroleptic treatment requirements.

  1980cited by this paper
• Prolactin response to neuroleptics. Clinical and theoretical implications.

  1980influential reference
• Effects of perphenazine enanthate injections on prolactin levels in plasma from schizophrenic women and men

  1978cited by this paper
• Comparative Endocrinology of Prolactin

  1977cited by this paper
• Drugs, neurotransmitters, and schizophrenia.

  1974cited by this paper
• Dopamine Nerve Terminals in the Rat Limbic Cortex: Aspects of the Dopamine Hypothesis of Schizophrenia

  1974cited by this paper
• The comparative endocrinology of prolactin.

  1968cited by this paper
• A Review of its Pharmacology and Therapeutic Potential in the Treatment of Schizophrenia

  year unknowncited by this paper

• The Effects of Antipsychotic Drugs and Non-Pharmacological Therapies on Schizophrenia

  2025cites this paper
• Assessment of prevalence of hyperprolactinemia in patients taking antipsychotic drugs in a tertiary care hospital in eastern India

  2024cites this paper
• A comparative study of sexual dysfunction in clinically stable schizophrenic patients receiving trifluoperazine, risperidone, and olanzapine

  2023cites this paper
• Risperidone-Induced Sexual Dysfunction Case Report

  2023cites this paper
• Comparative Study of Extrapyramidal Side Effects, Sexual Dysfunctions and Hyperprolactinaemia Using Typical and Atypical Antipsychotic Medications Among Patients with Schizophrenia in Maiduguri

  2023cites this paper
• Commentary on "Idiopathic granulomatous mastitis with normal prolactin level caused by risperidone".

  2022cites this paper
• Is Adjunct Aripiprazole Effective in Treating Hyperprolactinemia Induced by Psychotropic Medication? A Narrative Review

  2021cites this paper
• Prolactin response to antipsychotics: An inpatient study

  2020cites this paper
• Les dysfonctions sexuelles chez les patients souffrant d’ un trouble schizophrénique:traités par antipsychotiques. Une revue systématique de la littérature

  2020cites this paper
• Hyperprolactinaemia in the context of psychiatry

  2020influential citation
• Sexual dysfunctions in schizophrenia: Beyond antipsychotics. A systematic review.

  2019cites this paper
• Prolactin, flupenthixol decanoate and first episode schizophrenia – clinical and laboratory correlates

  2019cites this paper
• Psychosis, Antipsychotic Medication, and Sexual Dysfunctions

  2018cites this paper
• Women’s sexual dysfunction associated with psychiatric disorders and their treatment

  2018cites this paper
• A Comment on “Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia”

  2018cites this paper
• PROLACTIN LEVEL IN PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA TREATED FOR ONE YEAR WITH ATYPICAL ANTIPSYCHOTICS.

  2018cites this paper
• Sexual Dysfunctions in Mentally Ill Patients

  2018cites this paper
• Neuroleptic-Associated Hyperprolactinemia: Clinical Manifestations and Effects on Sexual Function

  2018cites this paper
• Prolactin levels: sex differences in the effects of risperidone, 9-hydroxyrisperidone levels, CYP2D6 and ABCB1 variants.

  2018cites this paper
• Antipsychotic-induced hyperprolactinaemia: case studies and review

  2017cites this paper
• Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation

  2017cites this paper
• Hyperprolactinaemia in first episode psychosis - A longitudinal assessment.

  2017cites this paper
• [Hyperprolactinemia associated with neuroleptic treatment: clinical characteristics and an impact on sexual function].

  2016cites this paper
• Pharmacokinetic patterns of risperidone-associated adverse drug reactions

  2016cites this paper
• Preliminary examination of microRNA expression profiling in bipolar disorder I patients during antipsychotic treatment

  2016cites this paper
• Early hyperprolactinaemia in acute psychiatric inpatients: a cross-sectional study

  2015cites this paper
• Serum Prolactin level in Thai Children and Adolescents with Autistic Spectrum Disorder on Long Term Risperidone Treatments

  2014cites this paper
• Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review

  2014cites this paper
• The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review

  2014cites this paper
• Non-neurological and metabolic side effects in the Cost Utility of the Latest Antipsychotics in Schizophrenia Randomised Controlled Trial (CUtLASS-1).

  2013cites this paper
• Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations.

  2013cites this paper
• The Pharmacological Role and Clinical Applications of Antipsychotics' Active Metabolites: Paliperidone versus Risperidone

  2013cites this paper
• Гиперпролактинемия,ассоциированная с приемом нейролептиков

  2013cites this paper
• Sexual Dysfunction Related to Psychotropic Drugs: A Critical Review Part II: Antipsychotics

  2013cites this paper
• Relationship between Prolactin Levels and Subjective Endocrine-Related Adverse Effects in Patients with Schizophrenia Receiving Long-Term Treatment with Amisulpride

  2012cites this paper
• Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis.

  2012cites this paper
• Antipsychotic-Induced Sexual Dysfunction and Its Management

  2012cites this paper
• Hyperprolactinemia induced by low‐dosage amisulpride in Korean psychiatric patients

  2012cites this paper
• IDIOPATHIC INTRACRANIAL HYPERTENSION IN A WOMAN WITH SCHIZOPHRENIA

  2012cites this paper
• A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics

  2011cites this paper
• Risk of osteoporosis and fracture incidence in patients on antipsychotic medication

  2011cites this paper
• Drugs and Pituitary Function

  2011cites this paper
• Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes.

  2011cites this paper
• DRD2 Taq1A Polymorphism Modulates Prolactin Secretion Induced by Atypical Antipsychotics in Healthy Volunteers

  2011cites this paper
• Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study

  2011cites this paper
• Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management

  2011cites this paper
• A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia

  2010influential citation
• PSYCHOTROPIC MEDICATION AND THE ENDOCRINE SYSTEM

  2010cites this paper
• The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone.

  2010cites this paper
• Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents.

  2009cites this paper
• An Agonist–Antagonist Interaction Model for Prolactin Release Following Risperidone and Paliperidone Treatment

  2009cites this paper
• Clinical questions and uncertainty — prolactin measurement in patients with schizophrenia and bipolar disorder

  2008influential citation
• Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder.

  2008cites this paper
• Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents.

  2008cites this paper
• Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin?

  2008cites this paper
• Antipsychotic-Induced Hyperprolactinemia: A Cross-Sectional Survey

  2008cites this paper
• A review of the association between antipsychotic use and hyperprolactinaemia

  2008cites this paper
• Five‐year follow‐up during antipsychotic treatment: efficacy, safety, functional and social outcome

  2007cites this paper
• Clinical decision‐making during 5 years of antipsychotic treatment

  2007cites this paper
• SCHIZOPHRENIA IN A LONGITUDINAL PERSPECTIVE clinical and neurocognitive aspects

  2007cites this paper